Histone Deacetylase 8 (HDAC8) Antibody (HDAC8-48): sc-56687
- Histone Deacetylase 8 (HDAC8) Antibody (HDAC8-48) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against full length HDAC8 of human origin
- recommended for detection of HDAC8 of human origin by WB, IP and ELISA
- See Histone Deacetylase 8 (E-5): sc-17778 for Histone Deacetylase 8 (HDAC8) antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Histone Deacetylase 8 (HDAC8) Antibody (HDAC8-48). This work is in progress.
HDAC8 Antibody (HDAC8-48) is a mouse monoclonal IgG1 antibody that detects HDAC8 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). HDAC8 is a crucial histone deacetylase primarily localized in the nucleus, where HDAC8 plays a significant role in regulating gene expression by removing acetyl groups from lysine residues on histones. This deacetylation process is vital for maintaining chromatin structure and function, as deacetylation leads to transcriptional repression and influences various cellular processes, including differentiation and proliferation. HDAC8′s importance extends beyond basic transcriptional regulation; HDAC8 has been implicated in the development of several cancers, making HDAC8 a potential target for therapeutic intervention. Additionally, HDAC8 interacts with various proteins, including transcription factors and other chromatin-modifying enzymes, which further underscores HDAC8′s role in complex regulatory networks governing gene expression. By utilizing anti-HDAC8 antibody (HDAC8-48), researchers can gain valuable insights into HDAC8′s functional dynamics and contributions to cellular processes and disease mechanisms.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Histone Deacetylase 8 (HDAC8) Antibody (HDAC8-48) References:
- HDAC8 inhibition ameliorates pulmonary fibrosis. | Saito, S., et al. 2019. Am J Physiol Lung Cell Mol Physiol. 316: L175-L186. PMID: 30358439
- Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview. | Banerjee, S., et al. 2019. Eur J Med Chem. 164: 214-240. PMID: 30594678
- Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway. | Zhao, T., et al. 2021. Front Pharmacol. 12: 677757. PMID: 33959033
- Downregulation of histone deacetylase 8 (HDAC8) alleviated the progression of oral submucous fibrosis. | Yang, HW., et al. 2023. J Dent Sci. 18: 652-658. PMID: 37021220
- Discovery of highly potent HDAC8 PROTACs with anti-tumor activity. | Zhao, C., et al. 2023. Bioorg Chem. 136: 106546. PMID: 37098288
- HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis. | Emmons, MF., et al. 2023. Nat Commun. 14: 7759. PMID: 38030596
- Activation of HDAC8 Can Suppress the Proliferation of Osteosarcoma Cells via TP53 and STAT3/ERK Signaling Pathways. | Wang, L., et al. 2023. Ann Clin Lab Sci. 53: 920-930. PMID: 38182151
- Sodium butyrate ameliorates high glucose-suppressed neuronal mitophagy by restoring PRKN expression via inhibiting the RELA-HDAC8 complex. | Cho, JH., et al. 2024. Autophagy. 20: 1505-1522. PMID: 38409852
- HDAC8 Enhances the Function of HIF-2α by Deacetylating ETS1 to Decrease the Sensitivity of TKIs in ccRCC. | Qian, K., et al. 2024. Adv Sci (Weinh). 11: e2401142. PMID: 39073752
- Combined HDAC8 and checkpoint kinase inhibition induces tumor-selective synthetic lethality in preclinical models. | Chang, TY., et al. 2024. J Clin Invest. 134: PMID: 39436709
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Histone Deacetylase 8 Antibody (HDAC8-48) | sc-56687 | 100 µg/ml | $316.00 |